World Health Organization Sounds Alert Over Severe Lack of Weight-Loss Jabs
Under a tenth of individuals that would benefit from obesity jabs like Wegovy are able to get them, warns the global health agency as it publishes its first guidance on the medications.
With more than one billion individuals worldwide currently classified as obese, it is calling for more widespread and fairer availability to these injectable treatments.
According to estimates, over two billion could be obese by 2030 if no action is taken.
"The new guidelines acknowledges that excess weight is a lifelong illness that can be addressed with holistic and lifelong care," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and logistical bottlenecks are major hurdles to broad availability to the treatments that can help people shift substantial weight, says the body.
GLP-1 Therapy Shortage
Even in the present most optimistic outlook, the production of such drugs could only cover approximately 100 million people – less than 10% of those who need them, per the health organization.
The advice encourages countries and companies to expand access, by measures including licensing agreements.
The intellectual property rights on a key compound – the core component of the drug Wegovy – is set to lapse in multiple countries in 2026.
How Weight-Loss Drugs Work
These medications replicate a body's own hormone to reduce digestion speed, curb appetite and enhance satiety so individuals eat less.
Individuals commonly begin shedding pounds within a few weeks of beginning the once-weekly jabs.
Research points to people may put most of the weight back on a year later of stopping the drug, because their usual hunger return.
Being carrying excess weight elevates your risk for developing diseases, like type 2 diabetes, cardiovascular issues, stroke, and certain malignancies.
Obesity affects individuals in every country and was responsible for 3.7 million fatalities worldwide in 2024, according to the WHO.